On August 20, Alan Bernstein and Arturo Casadevall discussed the state of rapid research into treatment and protection of COVID-19 patients. What can we learn from the 19th century technique of using antibody-rich plasma from survivors to treat the sick? What is the state of affairs with respect to international vaccine development? What unites these two tracks and what separates them?